Winner, Paul K.
Blumenfeld, Andrew M.
Eross, Eric J.
Orejudos, Amelia C.
Mirjah, Debbie L.
Adams, Aubrey Manack
Brin, Mitchell F.
Funding for this research was provided by:
Allergan plc
Article History
First Online: 17 May 2019
Compliance with Ethical Standards
:
: This study was sponsored by Allergan plc (Dublin, Ireland). The authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
: Paul K. Winner has received consulting fees/honoraria from Allergan, Amgen, and Supernus; has served on the speakers’ bureau for Allergan, Amgen, Avanir, and Supernus; and has received research grants from Allergan, Amgen, NuPathe, AstraZeneca, Avanir, Eli Lilly, and Novartis. Andrew M. Blumenfeld has served on advisory boards for Allergan, Amgen, Alder, Teva, Supernus, Lilly, Promius, and Eaglet, has received speaking fees from Allergan, Amgen, Pernix, Supernus, Depomed, Avanir and Promius, and holds patents on onabotulinumtoxinA in migraine that Allergan owns. Eric J. Eross has received grant/research support from Allergan; has served as an advisory board member/consultant for Amgen, Promius, and Supernus; has served on the speakers’ bureau for Allergan, Amgen, Avanir, Depomed, Pernix, Supernus, and Teva; and is the owner and president of Glia Sciences. Amelia Orejudos is an employee of Allergan plc. Debbie L. Mirjah, Aubrey Manack Adams, and Mitchell F. Brin are current or former employees of Allergan plc and own stock in the company.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study received ethical approval from the institutional review board or independent ethics committee at each site.
: Written informed consent was obtained from each patient prior to enrollment in the study.
: Data reported in this manuscript are available within the article and online resources. Additional data from the COMPEL Study (Clinical Trial Registration: ClinicalTrials.gov; NCT01516892) may be requested atExternalRef removed.